10 completed, 1 unknown. 4 Phase 3, 3 Phase 1, 3 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow Menactra: new trials by email Literature Review of Menactra trials Research Report on Menactra
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors Menactra - Preventive Immunization; Meningitis | Phase 4 | Unknown | Brigham and Women's Hospital | 102 | 2020-03-12 | 2022-11-15 |
| Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age NmCV-5, Menactra - Vaccine for Meningococcal Disease | Phase 2 / Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1640 | 2019-12-27 | 2021-09-08 |
| Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) NmCV-5, Menactra - Meningococcal Meningitis | Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1800 | 2019-08-20 | 2021-07-27 |
| Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali Pfs230D1M-EPA/AS01, HAVRIX, TYPHIM Vi (Salmonella typhi vaccine) - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1301 | 2019-04-24 | 2024-10-22 |
| Adolescent MenACWY Booster Study MenACWY-CRM, MenACWY-DT, MenACWY-TT - Meningococcal Disease, Invasive | Phase 4 | Completed | Canadian Immunization Research Network | 244 | 2018-09-20 | 2022-03-11 |
| Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Non-adjuvanted study formulation NmCV-5, Adjuvanted study formulation NmCV-5, Menactra - Meningitis, Meningococcal | Phase 2 | Completed | Serum Institute of India Pvt. Ltd. | 375 | 2017-11-15 | 2025-05-25 |
| Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali Pfs25M-EPA, Pfs230D1M-EPA, AS01 - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 301 | 2016-10-21 | 2024-12-10 |
| Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali Pfs230D1M-EPA/Alhydrogel, Pfs25M-EPA/Alhydrogel, TWINRIX - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 538 | 2015-01-07 | 2019-04-11 |
| Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine Pfs25-EPA/Alhydrogel, Euvax B, Menactra - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 230 | 2013-03-27 | 2018-07-05 |
| Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children MenACWY-CRM, Licensed meningococcal ACWY vaccine - Meningococcal Infections | Phase 3 | Completed | Novartis Vaccines | 2907 | 2008-03-01 | 2016-02-15 |
Malaria (4) · Meningitis, Meningococcal (3) · Meningitis (2) · Meningococcal Infections (2)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Serum Institute of India Pvt. Ltd. (3) · Brigham and Women's Hospital (1) · CanSino Biologics Inc. (1) · Canadian Immunization Research Network (1) · Novartis Vaccines (1)
Mali (6) · United States (3) · Canada (2) · India (1) · Indonesia (1) · The Gambia (1)
Patrick E Duffy, M.D. (3) · Dr Prasad Kulkarni, MD (1) · Isti Suharjanti, Dr (1) · Lindsey Baden, MD (1) · Manish Sadarangani, BM BCh DPhil (1) · Sara A Healy, M.D. (1)
PMID 39787798, PMID 20943209, PMID 30061051, PMID 31307393, PMID 33561016, PMID 34077644, PMID 37027391, PMID 37172200, PMID 37224196, PMID 37256991, PMID 37256992, PMID 37499679, PMID 39521012, PMID 40552966